Table 3.
Changes of serum lipid profile in fetal programming model after amlodipine-losartan combination treatment
Week | Blood sugar (mg/dL) | TG (mg/dL) | TC (mg/dL) | HDL-C (mg/dL) | LDL-C (mg/dL) | |
---|---|---|---|---|---|---|
4 | C | 288.50 ± 142.13 | 107.50 ± 62.98 | 84.33 ± 3.06 | 65.33 ± 11.93 | 18.00 ± 6.08 |
FR | 237.00 ± 108.43 | 142.00 ± 47.76 | 82.67 ± 2.52 | 66.67 ± 0.87 | 16.00 ± 4.58 | |
CX | 205.00 ± 0.00 | 83.00 ± 2.83 | 76.50 ± 2.12 | 65.50 ± 0.72 | 18.00 ± 0.00 | |
8 | C | 202.00 ± 14.72 | 45.75 ± 14.24 | 43.00 ± 6.78 | 40.50 ± 6.24 | 4.50 ± 1.00 |
FR | 207.50 ± 58.34 | 145.50 ± 26.80* | 62.75 ± 8.34 | 56.75 ± 0.85 | 7.50 ± 1.73 | |
CX | 263.00 ± 25.87 | 105.50 ± 28.63 | 62.75 ± 7.04 | 57.50 ± 5.45 | 9.25 ± 1.89 | |
12 | C | 127.75 ± 10.21 | 20.25 ± 10.31 | 42.25 ± 3.40 | 42.25 ± 2.99 | 5.75 ± 1.26 |
FR | 101.00 ± 18.17 | 38.25 ± 7.50* | 41.50 ± 7.59 | 42.00 ± 6.68 | 5.00 ± 2.16 | |
CX | 165.00 ± 94.69 | 30.00 ± 8.54 | 37.25 ± 22.51 | 37.00 ± 14.72 | 4.25 ± 3.86 | |
16 | C | 169.33 ± 3.33 | 62.50 ± 14.50 | 60.50 ± 12.82 | 52.00 ± 10.39 | 4.67 ± 0.47 |
FR | 189.50 ± 11.32 | 81.50 ± 0.32 | 54.25 ± 6.54 | 48.50 ± 12.84 | 5.00 ± 2.74 | |
CX | 191.67 ± 39.14 | 86.25 ± 32.93 | 54.50 ± 7.09 | 445.75 ± 4.44 | 5.00 ± 0.82 | |
20 | C | 141.17 ± 36.99 | 33.20 ± 13.31 | 48.50 ± 10.88 | 45.17 ± 9.70 | 5.33 ± 2.42 |
FR | 195.00 ± 22.58 | 76.80 ± 13.03* | 63.71 ± 17.74 | 56.71 ± 16.54 | 6.17 ± 3.29 | |
CX | 181.00 ± 19.61 | 42.75 ± 10.34† | 68.00 ± 24.99 | 63.40 ± 2.48 | 8.20 ± 3.49 |
C control, FR food restriction, CX amlodipine losartan-combination, TG triglyceride, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol
*C group vs FR group, p <0.05, † FR group vs CX group, p <0.05